Altintas Abdullah, Pasa Semir, Akdeniz Nurten, Cil Timucin, Yurt Murat, Ayyildiz Orhan, Batun Sabri, Isi Hilmi
Internal Medicine, Department of Hematology-Oncology, Dicle University, 21280, Diyarbakir, Turkey.
Ann Hematol. 2007 Oct;86(10):727-31. doi: 10.1007/s00277-007-0327-1. Epub 2007 Jun 16.
Factor V Leiden (FV-Leiden) and prothrombin gene mutations (FII G20210A) are well-established independent risk factors for thrombosis. In the recent years, many studies have suggested that these mutations are associated with an increased risk of recurrent pregnancy loss (RPL). We aimed to investigate the prevalence of these molecular defects in subjects with a history of early RPL. One hundred and fourteen women with three or more consecutive unexplained first-trimester miscarriages were compared to 185 parous women with uncomplicated pregnancies from the same ethnic origin. The presence of FV-Leiden and FII G20210A mutations was assessed by polymerase chain reaction analysis. Overall, 11 out of the 114 women with early RPL (9.6%) had either FV-Leiden or FII G20210A mutation, as compared with 16 out of the 185 women with normal pregnancies (8.6%; p = 0.756). The prevalence of FV-Leiden mutation was 7.9% (9/114) in patient group, compared with 7% (13/185) in control group (p = 0.780). One hundred and two patients were primary and 12 were secondary aborters. All FV-Leiden positive cases were primary aborters (8.8%; 9/102, p = 0.584). Concerning the FII G20210A, two out of 114 (1.7%) were first-trimester RPL (primary aborters) and three out of 185 (1.6%) controls were carriers of the FII G20210A mutation (1.7 vs 1.6%, p = 0.931). The results obtained from patients with first-trimester RPL and the control group have no statistical significant differences in the prevalence of FV-Leiden and FII G20210A mutations. These results suggest that mutations have no role in etiology of first-trimester recurrent abortions.
凝血因子V莱顿突变(FV-Leiden)和凝血酶原基因突变(FII G20210A)是公认的血栓形成独立危险因素。近年来,许多研究表明这些突变与复发性流产(RPL)风险增加有关。我们旨在调查有早期复发性流产病史的受试者中这些分子缺陷的患病率。将114名有三次或更多次连续不明原因的孕早期流产的女性与185名来自同一族裔、妊娠过程无并发症的经产妇进行比较。通过聚合酶链反应分析评估FV-Leiden和FII G20210A突变的存在情况。总体而言,114名早期复发性流产女性中有11名(9.6%)存在FV-Leiden或FII G20210A突变,而185名正常妊娠女性中有16名(8.6%)存在该突变(p = 0.756)。患者组中FV-Leiden突变的患病率为7.9%(9/114),对照组为7%(13/185)(p = 0.780)。102例患者为原发性流产者,12例为继发性流产者。所有FV-Leiden阳性病例均为原发性流产者(8.8%;9/102,p = 0.584)。关于FII G20210A,114名中有2名(1.7%)是孕早期复发性流产(原发性流产者),185名对照组中有3名(1.6%)是FII G20210A突变携带者(1.7%对1.6%,p = 0.931)。孕早期复发性流产患者和对照组在FV-Leiden和FII G20210A突变患病率方面的结果无统计学显著差异。这些结果表明,这些突变在孕早期复发性流产的病因中不起作用。